ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CFRX ContraFect Corporation

0.2318
0.00 (0.00%)
Mar 17 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.226
Ask Price 0.2261
News -
Day High

Low
0.20

52 Week Range

High
3.95

Day Low
Company Name Stock Ticker Symbol Market Type
ContraFect Corporation CFRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.2318 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.2318 0.2318
Trades Volume Avg Volume 52 Week Range
0 0 - 0.20 - 3.95
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.2318 USD

ContraFect Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.48M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

ContraFect News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CFRX Message Board. Create One! See More Posts on CFRX Message Board See More Message Board Posts

Historical CFRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.620.6880.200.4443698314,471-0.3882-62.61%
1 Year1.863.950.201.971,733,552-1.63-87.54%
3 Years427.20441.600.2033.291,862,327-426.97-99.95%
5 Years32.001,060.000.2064.291,325,108-31.77-99.28%

ContraFect Description

ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis.

Your Recent History

Delayed Upgrade Clock